Scancell Holdings Plc Company Profile (LON:SCLP)

About Scancell Holdings Plc (LON:SCLP)

Scancell Holdings Plc logoScancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: LON:SCLP
  • CUSIP: N/A
  • Web:
  • Market Cap: £33.35 million
  • Outstanding Shares: 261,558,000
Average Prices:
  • 50 Day Moving Avg: GBX 12.37
  • 200 Day Moving Avg: GBX 12.25
  • 52 Week Range: GBX 9.68 - GBX 17.88
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.03 per share
  • Price / Book: 4.25
  • EBIDTA: ($3,770,000.00)
  • Return on Equity: -37.54%
  • Return on Assets: -35.30%
  • Average Volume: 376,850 shs.

Frequently Asked Questions for Scancell Holdings Plc (LON:SCLP)

What is Scancell Holdings Plc's stock symbol?

Scancell Holdings Plc trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."

Where is Scancell Holdings Plc's stock going? Where will Scancell Holdings Plc's stock price be in 2017?

1 equities research analysts have issued 12-month price objectives for Scancell Holdings Plc's shares. Their predictions range from GBX 68 to GBX 68. On average, they expect Scancell Holdings Plc's share price to reach GBX 68 in the next twelve months. View Analyst Ratings for Scancell Holdings Plc.

Who are some of Scancell Holdings Plc's key competitors?

Who are Scancell Holdings Plc's key executives?

Scancell Holdings Plc's management team includes the folowing people:

  • Lindy Gillian Durrant, Chief Executive Officer, Executive Director
  • Richard Morley Goodfellow Ph.D., Joint Chief Executive Officer, Executive Director, Commercial Director
  • Sally Elizabeth Adams, Development Director, Director
  • John C. Chiplin Ph.D., Non-Executive Chairman of the Board
  • Katherine Cornish-Bowden, Non-Executive Director
  • Matthew G.W. Frohn, Non-Executive Director
  • Alan James Lewis Ph.D., Non-Executive Director

How do I buy Scancell Holdings Plc stock?

Shares of Scancell Holdings Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Scancell Holdings Plc's stock price today?

One share of Scancell Holdings Plc stock can currently be purchased for approximately GBX 12.75.

MarketBeat Community Rating for Scancell Holdings Plc (LON SCLP)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Scancell Holdings Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Scancell Holdings Plc (LON:SCLP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 68

Analysts' Ratings History for Scancell Holdings Plc (LON:SCLP)
DateFirmActionRatingPrice TargetDetails
7/11/2017Panmure GordonReiterated RatingBuyGBX 68View Rating Details
(Data available from 9/19/2015 forward)


Earnings History for Scancell Holdings Plc (LON:SCLP)
No earnings announcements for this company have been tracked by


Earnings Estimates for Scancell Holdings Plc (LON:SCLP)
Current Year EPS Consensus Estimate: $-1.20 EPS


Dividend History for Scancell Holdings Plc (LON:SCLP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Scancell Holdings Plc (LON:SCLP)
No insider trades for this company have been tracked by


Headline Trends for Scancell Holdings Plc (LON:SCLP)
Latest Headlines for Scancell Holdings Plc (LON:SCLP)
DateHeadline logoScancell Holdings Share Chat - July 16 at 8:02 PM logoScancell Holdings Plc (SCLP) Earns Buy Rating from Panmure Gordon - April 20 at 7:37 PM logoScancell Holdings Plc (SCLP) Given Buy Rating at Panmure Gordon - April 16 at 9:44 AM logoScancell’s (SCLP.L )Addario Lung Cancer Collaboration - March 17 at 7:48 PM logoHalf Year 2017 Scancell Holdings PLC Earnings Release - Before Market Open - January 31 at 10:43 PM logoSCLP: A Vanguard in Cancer Vaccines: 2 Platforms, 3 Products, 5 Indications - January 31 at 10:43 PM logoScancell Holdings Regulatory News - January 3 at 9:46 AM logoResults of AGM - London South East (registration) (blog) - October 18 at 7:04 PM


Social activity is not available for this stock.


Scancell Holdings Plc (SCLP) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff